Therapeutic advances in<scp>BIG</scp>3‐<scp>PHB</scp>2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer

Tetsuro Yoshimaru(National Institute of Biomedical Innovation, Health and Nutrition), Toyomasa Katagiri(National Institute of Biomedical Innovation, Health and Nutrition)
Cancer Science
March 3, 2015
10.1111/cas.12654
Cited by 15

Related Papers

Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|591
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|323
Mutation analysis in the BRCA2 gene in primary breast cancers
|Nature Genetics|1996|279
PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer
|Cancer Research|2006|180
Critical Roles of Mucin 1 Glycosylation by Transactivated Polypeptide <i>N</i> -Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis
|Cancer Research|2010|178